News & Insights
Feldman Legal Advisors’ Courtney Barnes, Esq. Advocates for Psilocybin Decriminalization in Connecticut
Courtney Barnes, Esq. was one of the policy reform activists who testified at the Psilocybin Decriminalization Forum that took place at the Connecticut Capitol last week. Organized by Last Prisoner Project, over a dozen therapists, researchers, attorneys, and advocates came together to speak about the value of psilocybin from both a mental health and economic perspective. The event marks the first psilocybin decriminalization informational forum of the 2024 legislative season.
Bipartisan Legislation Introduced to Regulate Hemp-Derived CBD
On July 20, 2023, the Hemp Access and Consumer Safety Act was reintroduced in the U.S. Congress. The long-awaited legislation, originally introduced in 2021, would require the U.S. Food and Drug Administration (FDA) to regulate ingestible hemp-derived cannabidiol (CBD) products the same as other foods, beverages, and dietary supplements.
Understanding the FDA’s New Guidelines for Psychedelic Drug Development and Research
The Food and Drug Administration (FDA) released draft guidance for researchers to consider when conducting clinical trials of the therapeutic benefits of psychedelic drugs.
New York Updates Proposed Adult Use Dispensary Regulations
Feldman Legal Advisors is pleased to share the recent changes to the New York State proposed adult use cannabis revised regulations, which were released by the Cannabis Control Board (CCB) and Office of Cannabis Management (OCM) last week.
What Does the New DEA Letter on THCO Mean for Novel Cannabinoids?
On February 13, 2023, the U.S. Drug Enforcement Administration (DEA) issued a regulatory opinion on the control status of tetrahydrocannabinol acetate ester (THCO), confirming that the agency classifies delta-8-THCO and delta-9-THCO as schedule 1 controlled substances.
